Oxaliplatin- induced neuropathy, Chemotherapy- induced neuropathy. Malignant neoplasm of overlapping sites of colon
Conditions
Interventions
Intervention 1: Intervention group: 1. receiving FOLFOX chemotherapy containing oxaliplatin receiving melatonin tablets ,One pill with a dose of 10 mg (manufactured by Jalinous pharmaceutical compa
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: All colon cancer patients with indication of adjuvant chemotherapy
Exclusion criteria
Exclusion criteria: All patients with history of DM or any form of peripheral nerve injury
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction rate in percentage of the incidence of neuropathy in the involved patients receiving melatonin. Timepoint: Symptoms of neuropathy asked from the patients in the form of some questionnaire before, in the first 48 hours of beginning of chemotherapy and 1week later, after every course of chemotherapy. Method of measurement: collection of the information in the form of questionnaires: NCI- CTCAE? OSNS, NPSI, EORTC QLQ- C??. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prophylaxis for neuropathy in patients with colon cancer under treatment with oxaliplatin an irreversible complication of this treatment. Timepoint: one and half a year. Method of measurement: By neuromuscular evaluation (EMG and NCV) and physical examination and questionere. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoma Razavidehkordi
Tehran University of Medical Sciences
Outcome results
None listed